FinnCap Reaffirms “Corporate” Rating for Allergy Therapeutics (AGY)

FinnCap reissued their corporate rating on shares of Allergy Therapeutics (LON:AGY) in a report issued on Wednesday. FinnCap currently has a GBX 47 ($0.65) price target on the stock.

Separately, Numis Securities reiterated a buy rating and set a GBX 45 ($0.62) target price on shares of Allergy Therapeutics in a research report on Tuesday, December 5th.

How to Become a New Pot Stock Millionaire

Shares of Allergy Therapeutics (AGY) opened at GBX 27.25 ($0.38) on Wednesday. Allergy Therapeutics has a one year low of GBX 23 ($0.32) and a one year high of GBX 39.50 ($0.55). The firm has a market cap of $148.26 and a P/E ratio of -2,725.00.

TRADEMARK VIOLATION NOTICE: This article was first reported by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this article on another website, it was illegally copied and reposted in violation of United States and international copyright law. The legal version of this article can be read at

About Allergy Therapeutics

Allergy Therapeutics Plc is a pharmaceutical company. The Company focuses on the treatment and prevention of allergy with aluminum-free products. The Company’s segments are Central Europe, which includes segments, such as Germany, Australia, Switzerland and the Netherlands; Southern Europe, which includes Italy and Spain; the United Kingdom, and Rest of World.

Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply